PMID- 7506802
OWN - NLM
STAT- MEDLINE
DCOM- 19940217
LR  - 20171116
IS  - 0368-2811 (Print)
IS  - 0368-2811 (Linking)
VI  - 23
IP  - 6
DP  - 1993 Dec
TI  - Acute myeloid leukemia possibly producing thrombopoietic factor(s).
PG  - 366-72
AB  - A 75-year-old man developed a cluster of differentiation (CD)4-positive but human 
      T-cell lymphotropic virus type I (HTLV-I)-negative T lymphoid neoplasm with 
      overwhelming cutaneous involvement and mild thrombocytosis. Twelve courses 
      tetrahydropyranyl adriamycin, cyclophosphamide, vincristine and prednisone 
      (THP-COP) combination chemotherapy led him to complete remission. After four 
      months of complete remission, however, atypical immature cells (blasts) appeared 
      in peripheral blood and bone marrow. Surface marker analysis revealed the blasts 
      to be CD2-, CD3-, CD4-, CD5-, CD7+, CD8-, CD10, CD13 +/-, CD19-, CD20-, CD25-, 
      CD33+ and human leukocyte antigen-DR (HLA-DR+). Staining for myeloperoxidase, 
      esterases, PAS and platelet peroxidase were all negative. The patient was 
      diagnosed as having both CD7 and CD33 positive acute myeloid leukemia (AML). The 
      relation between the T cell lymphoid neoplasm and AML was not clear. 
      Thrombocytosis became more marked after acute leukemia occurred and the platelet 
      count varied in parallel with the blast cell count in peripheral blood. When the 
      leukemic cell count was high, thrombopoietic activity could be detected in the 
      serum. In addition, conditioned medium obtained from primarily-cultured blasts 
      had detectable thrombopoietic activity, which implied the blasts directly to 
      produce a thrombopoietic factor(s). Analysis of the serum concentration for 
      cytokines with associated thrombopoietic activity indicated that the blasts 
      possibly produced a thrombopoietic factor(s) distinct from interleukin (IL)6, 
      IL3, leukemia inhibitory factor (LIF), erythropoietin and granulocyte 
      macrophage-colony stimulating factor. To our knowledge, this is the first 
      reported case of an acute myeloid leukemia with marked thrombopoiesis (more than 
      2000 x 10(3)/microliter of maximum platelet count in peripheral blood.
FAU - Fujita, A
AU  - Fujita A
AD  - Fourth Department of Internal Medicine, Faculty of Medicine, University of Tokyo.
FAU - Matsuoka, M
AU  - Matsuoka M
FAU - Shimonaka, Y
AU  - Shimonaka Y
FAU - Imai, N
AU  - Imai N
FAU - Asano, S
AU  - Asano S
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Jpn J Clin Oncol
JT  - Japanese journal of clinical oncology
JID - 0313225
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, CD7)
RN  - 0 (Antigens, Differentiation, Myelomonocytic)
RN  - 0 (Antigens, Differentiation, T-Lymphocyte)
RN  - 0 (CD33 protein, human)
RN  - 0 (CD4 Antigens)
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (Interleukin-3)
RN  - 0 (Interleukin-6)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Sialic Acid Binding Ig-like Lectin 3)
RN  - EC 3.1.1.7 (Acetylcholinesterase)
SB  - IM
MH  - Acetylcholinesterase/metabolism
MH  - Acute Disease
MH  - Aged
MH  - Antigens, CD/analysis
MH  - Antigens, CD7
MH  - Antigens, Differentiation, Myelomonocytic/analysis
MH  - Antigens, Differentiation, T-Lymphocyte/analysis
MH  - Bone Marrow/pathology/physiopathology
MH  - CD4 Antigens/analysis
MH  - Cell Adhesion Molecules/analysis
MH  - *Hematopoiesis/physiology
MH  - Humans
MH  - Interleukin-3/pharmacology
MH  - Interleukin-6/pharmacology
MH  - Leukemia, Myeloid/*blood/pathology/physiopathology
MH  - Male
MH  - Megakaryocytes/pathology/physiology
MH  - Membrane Glycoproteins/analysis
MH  - Sialic Acid Binding Ig-like Lectin 3
MH  - Skin Neoplasms/*blood/pathology/physiopathology
MH  - Thrombocytosis/*pathology/physiopathology
EDAT- 1993/12/01 00:00
MHDA- 1993/12/01 00:01
CRDT- 1993/12/01 00:00
PHST- 1993/12/01 00:00 [pubmed]
PHST- 1993/12/01 00:01 [medline]
PHST- 1993/12/01 00:00 [entrez]
PST - ppublish
SO  - Jpn J Clin Oncol. 1993 Dec;23(6):366-72.